Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).

Authors

Christopher G Cann

Vanderbilt University Medical Center, Nashville, TN

Christopher G Cann , Sarah Cimino , Brian Grieb , Kristen Keon Ciombor , Rajiv Agarwal , Satya Das , Laura Williams Goff , Dana Backlund Cardin , Shemeka Davis , Casey Fletcher , Jordan Berlin , Cathy Eng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Updated analysis: Effect of biweekly dosing schedule of trifluridine-tipiracil (TAS-102) on rates of myelosuppression and maintenance of therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).

First Author: Christopher G Cann

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).

First Author: Patrick M Boland

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Regorafenib (REGO) plus FOLFIRINOX as frontline treatment in patients (pts) with RAS-mutated metastatic colorectal cancer (mCRC): A phase I/II, dose-escalation and dose-expansion study.

First Author: Antoine Adenis

insert_chart_outlined

Poster

2021 Gastrointestinal Cancers Symposium

bookmark_border

Quadruplet regimen with capecitabine, irinotecan, oxaliplatin, and bevacizumab in chemo-naive patients with metastatic colorectal cancer: Results from the safety lead-in of QUATTRO-II study.

First Author: Hideaki Bando